GlassScriptPhysician profile
Freya Mendoza
NPI 1700859089
$2,099.21
in general payments reported to CMS, 2019-2025
14 companies · $46.17 in 2025
The $46.17 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $33.57 · 2021: $209 · 2022: $278 · 2023: $186 · 2024: $909 · 2025: $46.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.97 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $279.79 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $273.66 | 2021-2024 | Xarelto |
| Amgen INC. | $258.35 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $121.60 | 2024 | |
| Phathom Pharmaceuticals, INC. | $121.60 | 2024 | Voquezna |
| Lilly USA, LLC | $102.42 | 2022-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $57.54 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $45.94 | 2020-2021 | |
| Pfizer INC. | $37.53 | 2022-2023 | |
| Novo Nordisk INC | $27.40 | 2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.79 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freya Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.